This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Rx
Fulvestrant
250 mg/5 ml, Roztwór do wstrzykiwań
INN: Fulvestrantum
Data updated: 2026-04-13
Available in:
🇨🇿🇩🇪🇬🇧🇫🇷🇵🇱🇵🇹🇸🇰🇹🇷🇺🇦
Form
Roztwór do wstrzykiwań
Dosage
250 mg/5 ml
Route
domięśniowa
Storage
Storage REFRIGERATE, 2° to 8°C (36° to 46°F). TO PROTECT FROM LIGHT, STORE IN THE ORIGINAL CARTON UNTIL TIME OF USE. Sterile, Nonpyrogenic, PVC-free, DEHP-free.
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
About This Product
Manufacturer
AstraZeneca AB (Szwecja)
Composition
Fulvestrantum 250 mg/5 ml
ATC Code
L02BA03
Source
URPL
11 DESCRIPTION Fulvestrant Injection for intramuscular administration is an estrogen receptor antagonist. The chemical name is 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)-triene-3,17-beta-diol. The molecular formula is C 32 H 47 F 5 O 3 S and its structural formula is: Fulvestrant is a white powder with a molecular weight of 606.77. The solution for injection is a clear, colorless to yellow, viscous liquid. Each injection contains as inactive ingredients: 10% w/v (12% v/v) Alcohol, USP, 10% w/v Benzyl Alcohol, NF, and 15% w/v Benzyl Benzoate, USP, as co-solvents, and made up to 100% w/v with Castor Oil, USP as a co-solvent and release rate modifier. Structural Formula
⚠️ Warnings
Instructions for administration
Administer the injection according to the local guidelines for performing large volume intramuscular injections.
NOTE: Due to the proximity of the underlying sciatic nerve, caution should be taken if administering Faslodex at the dorsogluteal injection site (see section 4.4).
Warning - Do not autoclave safety needle (BD SafetyGlide Shielding Hypodermic Needle) before use. Hands must remain behind the needle at all times during use and disposal.
For each of the two syringes:
• Remove glass syringe barrel from tray and check that it is not damaged.
• Peel open the safety needle (SafetyGlide) outer packaging.
• Parenteral solutions must be inspected visually for particulate matter and discolouration prior to administration.
• Hold the syringe upright on the ribbed part (C). With the other hand, take hold of the cap (A) and carefully tilt back and forth until the cap disconnects and can be pulled off, do not twist (see Figure 1).
• Remove the cap (A) in a straight upward direction. To maintain sterility do not touch the syringe tip (B) (see Figure 2).
• Attach the safety needle to the Luer-Lok and twist until firmly seated (see Figure 3).
• Check that the needle is locked to the Luer connector before moving out of the vertical plane.
• Pull shield straight off needle to avoid damaging needle point.
• Transport filled syringe to point of administration.
• Remove needle sheath.
• Expel excess gas from the syringe.
• Administer intramuscularly slowly (1‑2 minutes/injection) into the buttock (gluteal area). For user convenience, the needle bevel-up position is oriented to the lever arm (see Figure 4).
• After injection, immediately apply a single-finger stroke to the activation assisted lever arm to activate the shielding mechanism (see Figure 5).
NOTE: Activate away from self and others. Listen for click and visually confirm needle tip is fully covered.
Disposal
Pre-filled syringes are for single use
only
.
This medicine may pose a risk to the aquatic environment. Any unused medicinal product or waste material should be disposed of in accordance with local requirements (see section 5.3).